medigraphic.com
Instituto Nacional de Salud Pública

2021, Number 1

<< Back Next >>

salud publica mex 2021; 63 (1)

Criteria for returning to work and determination of the vulnerability value for Covid-19

Velasco-Reyna R, Hernández-Ávila M, Méndez-Santa Cruz JD, Ortega-Álvarez MC, Ramírez-Polanco EA, Real-Ornelas GA, Toral-Villanueva R, Tinajero-Sánchez JC, López-Flores H, Flores-Rodríguez D

Language: Spanish
References: 73
Page: 136-146
PDF size: 278.07 Kb.


ABSTRACT

Objective. To establish medical criteria for return to work to people with increased risk of severe illness from Covid-19. Materials and methods. We performed a systematic review to identify the conditions and clinical characteristics that influence the risk of developing severe Covid-19. Results. Increased risk has been shown in obesity, age ›60 years old, diabetes mellitus, arterial hypertension, chronic obstructive pulmonary disease, cardiovascular disease, chronic kidney disease and cancer. Only in diabetes it has been studied whether prior control influences. Specific medical conditions and epidemiological risk level for return to work are proposed. Conclusions. Return to work of vulnerable groups should be prioritized, seeking to promote disease control, identifying health conditions that increase risk, and protecting the right to work. We present recommendations to guide the return to work.


REFERENCES

  1. Secretaría de Salud. Acuerdo por el que se establecen los lineamientos técnicos específicos para la reapertura de las actividades económicas. México: Diario Oficial de la Federación, 2020 [citado julio 1, 2020]. Disponible en: https://www.dof.gob.mx/nota_detalle.php?codigo=5594138&fech a=29/05/2020&print=true

  2. Inslee J. Proclamation by the governor amending proclamations 20-05. Washington: Washington Government, 2020 [citado julio 1, 2020]. Disponible en: https://www.governor.wa.gov/sites/default/files/20-46%20-%20 COVID-19%20High%20Risk%20Employees.pdf?utm_medium=email&utm_ source=govdelivery

  3. Preskorn SH. The 5% of the population at high risk for severe COVID- 19 infection Is identifiable and needs to be taken into account when reopening the economy. J Psychiatr Pract. 2020;26(3):219-27. https://doi. org/10.1097/PRA.0000000000000475

  4. Instituto Nacional de Salud Pública. Encuesta nacional de salud y nutrición 2018: Presentación de resultados. México: INSP, 2018 [citado julio 1, 2020]. Disponible en: https://ensanut.insp.mx/encuestas/ensanut2018/ doctos/informes/ensanut_2018_presentacion_resultados.pdf

  5. International Labour Organization. ILO Monitor: COVID-19 and the world of work. Fourth edition. Ginebra: ILO, 2020 [citado junio 01, 2020]. Disponible en: https://reliefweb.int/sites/reliefweb.int/files/resources/ ILO%20Monitor%20-%20COVID-19%20and%20the%20world%20of%20 work.%20Fourth%20edition.pdf

  6. International Labour Organization. A safe and healthy return to work during the COVID-19 pandemic. Ginebra: ILO, 2020 [citado junio 6, 2020]. Disponible en: https://www.ilo.org/wcmsp5/groups/public/---ed_protect/--- protrav/---safework/documents/briefingnote/wcms_745549.pdf

  7. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049-57. https://doi.org/10.18632/aging.103000

  8. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-5. https:// doi.org/10.1016/j.ijid.2020.03.017

  9. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110-8. https://doi.org/10.1016/j.jaci.2020.04.006

  10. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest. 1989;95(suppl 2):2S-4S.

  11. Gobierno de México. Criterios para las poblaciones en situación de vulnerabilidad que pueden desarrollar una complicación o morir por COVID-19 en la reapertura de actividades económicas en los centros de trabajo. México: Gobierno de México, 2020 [citado julio 28, 2020]. Disponible en: https://coronavirus.gob.mx/wp-content/uploads/2020/07/ Criterios_vulnerabilidad_27Julio2020.pdf

  12. World Health Organization. Clinical management of COVID-19. Ginebra: WHO, 2020 [citado junio 6, 2020]. Disponible en: https://www.who. int/publications/i/item/clinical-management-of-covid-19

  13. Mullins E, Evans D, Viner RM, O’Brien P, Morris E. Coronavirus in pregnancy and delivery: rapid review. Ultrasound Obstet Gynecol. 2020;55(5):586-92. https://doi.org/10.1002/uog.22014

  14. Ahlberg M, Neovius M, Saltvedt S, Söderling J, Pettersson K, Brandkvist C, Stephansson O. Association of SARS-CoV-2 Test Status and Pregnancy Outcomes. JAMA. 2020:e2019124. https://doi.org/ 10.1001/ jama.2020.19124

  15. Dashraath P, Wong JLJ, Lim MXK, Lim LM, Li S, Biswas A, et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am J Obstet Gynecol. 2020;222(6):521-31. https://doi.org/10.1016/j.ajog.2020.03.021

  16. Juan J, Gil MM, Rong Z, Zhang Y, Yang H, Poon LC. Effects of coronavirus disease 2019 (COVID-19) on maternal, perinatal and neonatal outcomes: a systematic review. Ultrasound Obstet Gynecol. 2020;56(1):15-27. https://doi.org/10.1002/uog.22088

  17. Davanzo R, Moro G, Sandri F, Agosti M, Moretti C, Mosca F. Breastfeeding and coronavirus disease-2019: Ad interim indications of the Italian Society of Neonatology endorsed by the Union of European Neonatal & Perinatal Societies. Matern Child Nutr. 2020;16(3):e13010. https://doi. org/10.1111/mcn.13010

  18. Giuliani C, Li Volsi P, Brun E, Chiambretti A, Giandalia A, Tonutti L, et al. Breastfeeding during the COVID-19 pandemic: suggestions on behalf of Woman Study Group of AMD. Diabetes Res Clin Pract. 2020;165:108239. https://doi.org/10.1016/j.diabres.2020.108239

  19. Fernández-Carrasco FJ, Vázquez-Lara JM, González-Mey U, Gómez- Salgado J, Parrón-Carreño T, Rodríguez-Díaz L. Infección por coronavirus Covid-19 y lactancia materna: una revisión exploratoria. Rev Esp Salud Publica. 2020;94(1):e1-e9 [citado julio 1, 2020]. Disponible en: https:// www.mscbs.gob.es/biblioPublic/publicaciones/recursos_propios/resp/revista_ cdrom/VOL94/REVISIONES/RS94C_202005055.pdf

  20. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2020;14(4):395-403. https://doi.org/10.1016/j.dsx.2020.04.018

  21. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Internal Med. 2020;180(7):934-43. https://doi.org/10.1001/jamainternmed.2020.0994

  22. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the chinese center for disease control and prevention. JAMA 2020;323(13):1239-1242. https://doi.org/10.1001/ jama.2020.2648

  23. Holman N, Knighton P, Kar P, O’Keefe J, Curley M, Weaver A, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes and COVID-19 related mortality in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020;8(10):823-33. https://doi. org/10.1016/S2213-8587(20)30271-0

  24. Cecilia C, Claudia A, Joana M, Rute N, Bruno S. SARS-CoV-2 and diabetes: New challenges for the disease. Diabetes Res Clin Pract. 2020;164:108228. https://doi.org/10.1016/j.diabres.2020.108228

  25. Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of blood glucose control and outcomes in patients with COVID-19 and Preexisting Type 2 Diabetes. Cell Metab. 2020;31(6):1068-77.e3. https://doi. org/10.1016/j.cmet.2020.04.021

  26. Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and metaregression. J Renin Angiotensin Aldosterone Syst. 2020;21(2). https://doi. org/10.1177/1470320320926899

  27. Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. Am J Hypertens. 2020;33(5):373-4. https://doi.org/10.1093/ajh/ hpaa057

  28. Centro Nacional de Excelencia Tecnológica en Salud. Diagnóstico y tratamiento de la hipertensión arterial en el primer nivel de atención: Evidencias y recomendaciones. México: CENETEC, 2014 [citado junio 1, 2020] Disponible en: http://www.cenetec.salud.gob.mx/descargas/gpc/ CatalogoMaestro/076-GCP__HipertArterial1NA/HIPERTENSION_EVR_ CENETEC.pdf

  29. Kannel WB. Hypertension: reflections on risks and prognostication. Med Clin North Am. 2009;93(3):541-58. https://doi.org/10.1016/j. mcna.2009.02.006

  30. Kassir R. Risk of COVID-19 for patients with obesity. Obes Rev. 2020;21(6):e13034. https://doi.org/10.1111/obr.13034

  31. Petrilli C, Jones S, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966. https://doi.org/10.1136/bmj.m1966

  32. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, Stachel A. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis. 2020:71(15):896-7. https:// doi.org/10.1093/cid/ciaa415

  33. Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, Mylonakis E. Association of obesity with disease severity among patients with coronavirus disease 2019. Obesity (Silver Spring). 2020;28(7):1200-4. https://doi.org/10.1002/oby.22859

  34. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus- 2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020;28(7):1195-9. https://doi.org/10.1002/oby.22831

  35. Li J, Li SX, Zhao LF, Kong DL, Guo ZY. Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic. Chronic Dis Transl Med. 2020;6(2):119- 23. https://doi.org/10.1016/j.cdtm.2020.05.001

  36. Wang X, Fang X, Cai Z, Wu X, Gao X, Min J, Wang F. Comorbid chronic diseases and acute organ injuries are strongly correlated with disease severity and mortality among COVID-19 patients: a systemic review and meta-analysis research (Wash DC). 2020;2020:2402961. https://doi. org/10.34133/2020/2402961

  37. Chou CY, Wang SM, Liang CC, Chang CT, Liu JH, Wang IK, et al. Risk of pneumonia among patients with chronic kidney disease in outpatient and inpatient settings: a nationwide population-based study. Medicine (Baltimore). 2014;93(27):e174. https://doi.org/10.1097/MD.0000000000000174

  38. International Society of Nephrology. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. 2013;3(1):107. https://doi.org/10.1038/kisup.2012.74

  39. Bonanad C, García BS, Tarazona SF, Diez VP, Ayezta A, Sanchis FJ, et al. Coronavirus: la emergencia geriátrica de 2020. Documento conjunto de la Sección de Cardiología Geriátrica de la Sociedad Española de Cardiología y la Sociedad Española de Geriatría y Gerontología. Rev Esp Cardiol. 2020;73(7):569-76. https://doi.org/10.1016/j.recesp.2020.03.027

  40. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect. 2020;80(6):e14-e18. https://doi.org/10.1016/j.jinf.2020.03.005

  41. Liu W, Tao ZW, Wang L, Yuan ML, Liu K, Zhou L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl). 2020;133(9):1032-8. https://doi. org/10.1097/CM9.0000000000000775

  42. Banerjee D. ‘Age and ageism in COVID-19’: Elderly mental health-care vulnerabilities and needs. Asian J Psychiatr. 2020;51:102154. https://doi. org/10.1016/j.ajp.2020.102154

  43. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J Med Virol. 2020;92(10):1915-21. https://doi. org/10.1002/jmv.25889

  44. Cen Y, Chen X, Shen Y, Zhang XH, Lei Y, Xu C, et al. Risk factors for disease progression in patients with mild to moderate COVID-19 patients- coronavirus disease 2019-a multi-center observational study. Clin Microbiol Infect. 2020;26(9):1242-7. https://doi.org/10.1016/j. cmi.2020.05.041

  45. Flick H, Arns BM, Bolitschek J, Bucher B, Cima K, Gingrich E, et al. Management of patients with SARS-CoV-2 infections and of patients with chronic lung diseases during the COVID-19 pandemic (as of 9 May 2020): Statement of the Austrian Society of Pneumology (ASP). Wien Klin Wochenschr. 2020;132(13):365-86. https://doi.org/10.1007/s00508-020-01691-0

  46. American Thoracic Society. Pulmonary Function Laboratories: Advice Regarding COVID-19. New York: ATS, 2020 [citado junio 6, 2020] Disponible en: https://www.thoracic.org/professionals/clinical-resources/diseaserelated- resources/pulmonary-function-laboratories.php

  47. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164. https://doi. org/10.1183/13993003.00164-2019

  48. Jones PW, Tabberer M, Chen WH. Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT™) scores. BMC Pulm Med. 2011;11:42. https://doi.org/10.1186/1471-2466-11-42

  49. Underner M, Peiffer G, Perriot J, Jaafari N. Asthme et COVID-19: une population à risque? Rev Mal Respir. 2020;37(7):606-7. https://doi. org/10.1016/j.rmr.2020.05.002

  50. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with different severities: a multicenter study of clinical features. Am J Respir Crit Care Med. 2020;201(11):1380-8. https://doi.org/10.1164/rccm.202002-0445OC

  51. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730-41. https://doi.org/10.1111/all.14238

  52. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574-81. https://doi.org/10.1001/jama.2020.5394

  53. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-9. https://doi.org/10.1001/jama.2020.6775

  54. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. https://doi.org/10.1136/ bmj.m1985

  55. Pennington E. Asthma increases risk of severity of COVID-19. Cleve Clin J Med. 2020. https://doi.org/10.3949/ccjm.87a.ccc002

  56. Global Initiative for Asthma. Global strategy for asthma management and prevention. Estados Unidos: GINA, 2020 [citado julio 8, 2020]. Disponible en: https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020- report_20_06_04-1-wms.pdf

  57. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-6. https://doi.org/10.1038/s41586-020-2521-4

  58. Centers for Disease Control and Prevention. People with Moderate to Severe Asthma. Estados Unidos: CDC, 2020 [citado julio 8, 2020]. Disponible en: https://www.cdc.gov/coronavirus/2019-ncov/need-extraprecautions/ asthma.html

  59. San Román JA, Uribarri A, Amat-Santos IJ, Aparisi A, Catalá P, González- Juanatey JR. La presencia de cardiopatía agrava el pronóstico de los pacientes con COVID-19. Rev Esp Cardiol. 2020;73(9):773-5. https://doi. org/10.1016/j.recesp.2020.05.022

  60. Aggarwal G, Lippi G, Michael-Henry B. Cerebrovascular disease is associated with an increased disease severity in patients with Coronavirus Disease 2019 (COVID-19): A pooled analysis of published literature. Int J Stroke. 2020;15(4):385-9. https://doi.org/10.1177/1747493020921664

  61. Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859-66. https://doi.org/10.1136/annrheumdis-2020-217871

  62. Ceribelli A, Motta F, De Santis M, Ansari AA, Ridgway WM, Gershwin ME, Selmi C. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. J Autoimmun. 2020;109:102442. https://doi.org/10.1016/j.jaut.2020.102442

  63. Vishnevetsky A, Levy M. Rethinking high-risk groups in COVID-19. Mult Scler Relat Disord. 2020;42:102139. https://doi.org/10.1016/j. msard.2020.102139

  64. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335-7. https://doi.org/10.1016/S1470-2045(20)30096-6

  65. Joob B, Wiwanitkit V. SARS-CoV-2 and HIV. J Med Virol. 2020;92(9):1415. https://doi.org/10.1002/jmv.25782

  66. Härter G, Spinner CD, Roider J, Bickel M, Krznaric I, Grunwald S, et al. COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients. Infection. 2020:1-6. https://doi.org/10.1007/s15010- 020-01438-z

  67. Instituto Mexicano del Seguro Social. Tratamiento antirretroviral del paciente adulto con infección por el VIH: Evidencias y recomendaciones. México: IMSS, 2011 [citado julio 8, 2020]. Disponible en: http://www.imss. gob.mx/sites/all/statics/guiasclinicas/245GER.pdf

  68. Lucero C, Torres B, León A, Calvo M, Leal L, Pérez I, et al. Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells/mm³. AIDS Res Hum Retroviruses. 2013;29(8):1161-7. https://doi.org/10.1089/AID.2012.0367

  69. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. https://doi. org/10.1183/13993003.00547-2020

  70. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázquez A, González-Díaz A, Márquez-Salinas A, et al. Predicting mortality due to SARS-CoV-2: A mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico. J Clin Endocrinol Metab. 2020;105(8):dgaa346. https://doi. org/10.1210/clinem/dgaa346

  71. Rueda GJ, Vicente HM, Campo MT, Reinoso LB, De la Hoz RE, Delclos GL, et al. Return to work guidelines for the COVID-19 pandemic. Occupational Medicine. 2020;70(5):300-5. https://doi.org/10.1093/occmed/ kqaa099

  72. Occupational Safety and Health Administration. Guidance on Returning to Work. Estados Unidos: U.S. Department of Labor [citado julio 6, 2020]. Disponible en: https://www.osha.gov/Publications/OSHA4045.pdf

  73. Ministerio de sanidad. Procedimiento de actuación para los servicios de prevención de riesgos laborales frente a la exposición al SARS-CoV-2. España: Gobierno de España, 2020 [citado julio 6, 2020]. Disponible en: https:// www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov- China/documentos/20200619Proteccion_Trabajadores_SARS-CoV-2.pdf




2020     |     www.medigraphic.com